New study shows promise of ALung’s Hemolung technology to help protect the injured lung

Study results published in the journal Critical Care show that the Hemolung RAS can safely facilitate an ultra-protective ventilation strategy. PITTSBURGH  (February 15, 2016) – ALung Technologies, Inc., a leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced today the publication of new results from an (read more)

Case series of protective ventilation for ARDS using partial extracorporeal CO2 removal

Rauch S.1, Roth H.2, Deininger T.2, Kuhwald A.2, Lund L.3, Fischer M.1 1ALB FILS KLINIKEN, Anesthesiology, Göppingen, Germany, 2ALB FILS KLINIKEN, Internal Medicine, Göppingen, Germany, 3ALung Technologies Inc., Pittsburgh, United States Poster presentation from the EuroELSO 2015 4th International Congress Objectives In the ARDS Network trial of low tidal volume ventilation, hypercapnia and respiratory acidosis (read more)